Gongwin Biopharm Holdings Co 6617.TWO · TWD

Its shares trade on Taipei Exchange under the ticker 6617.TWO. It has been listed since 8 February 2017. In the fiscal year to 31 December 2025, it reported revenue of TWD 36.4m and a net loss of TWD 114.1m. At that date it held total assets of TWD 2.80bn and shareholders' equity of TWD 2.53bn.

Gongwin Biopharm Holdings Co., Ltd. engages in the operation of Minimally Invasive Targeted Tumor Ablation business. The company is headquartered in Taipei City, Taipei. The company went IPO on 2017-02-08. The Company’s headquarter is located in Taiwan and it created a cross-regional platform composed of Taiwan, China Mainland and the United States. The new PTS drug researched and developed by the Company is a new drug product for cancer treatment combined with minimally invasive interventional therapy technology, including PTS100 for the treatment of liver cancer, PTS302 for the treatment of lung cancer, PTS-02 for the treatment of rare diseases, PTS500 for the treatment of malignant pleural effusion and pets medication GWA101 and others.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Lester WuChairman of the Board, since 2016TWD 4.7m
• Mr. Wei Nan HuChief Financial Officer, Corporate Governance Officer
• Mr. Si LiuGeneral Manager-Tianjin
• Mr. Mao Yuan LinGeneral Manager, Director, since 2014
• Ms. Li TianDeputy General Manager-Tianjin
• Mr. Charles YangDeputy General Manager
• Ms. Shaowen GuoDirectorTWD 420,000
• Mr. Jixiu LiuDirectorTWD 48,000
• Youhua YangDirector
• Mr. Lielin ZhanDirectorTWD 42,000
• Ms. Jingru WuIndependent DirectorTWD 388,000
• Mr. Zhidong YangIndependent DirectorTWD 382,000

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.